| Mandy Boltz, MD | |
|
1300 N 12th St, Suite 605, Phoenix, AZ 85006-2848 | |
| (602) 839-4567 | |
| Not Available |
| Full Name | Mandy Boltz |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 1300 N 12th St, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124481353 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2222222 (Arizona) | Primary |
| Entity Name | Wesley Community Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396910436 PECOS PAC ID: 9032264239 Enrollment ID: O20100407000432 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
Carbon nanotubes, one of the original engineered nanomaterials, also may prove to be among the most versatile, as numerous teams of investigators continue to develop novel nanotube-based therapeutic and diagnostic tools. Over the past month, three new research papers have highlighted the potential of nanotubes as weapons against cancer.
Now that the badly botched rollout of the federal government's health care website seems to be behind us, Republicans have shifted their criticisms to several states that are experiencing problems enrolling people on their state-run exchanges.
Violence against children in residential institutions can be found across Europe and Central Asia, according to research gathered by UNICEF in the run-up to a major conference on violence against children. The research also reveals glaring gaps in knowledge and data.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mandy Boltz, MD 1300 N 12th St, Suite 605, Phoenix, AZ 85006-2848 Ph: (602) 839-4567 | Mandy Boltz, MD 1300 N 12th St, Suite 605, Phoenix, AZ 85006-2848 Ph: (602) 839-4567 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
Carbon nanotubes, one of the original engineered nanomaterials, also may prove to be among the most versatile, as numerous teams of investigators continue to develop novel nanotube-based therapeutic and diagnostic tools. Over the past month, three new research papers have highlighted the potential of nanotubes as weapons against cancer.
Now that the badly botched rollout of the federal government's health care website seems to be behind us, Republicans have shifted their criticisms to several states that are experiencing problems enrolling people on their state-run exchanges.
Violence against children in residential institutions can be found across Europe and Central Asia, according to research gathered by UNICEF in the run-up to a major conference on violence against children. The research also reveals glaring gaps in knowledge and data.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
› Verified 8 days ago
Dr. Serena Dawn Woods-grimm, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 201 N Central Ave, Phoenix, AZ 85004 Phone: 602-221-6326 | |
Michael Devin Taylor, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2927 N 7th Ave, Peppertree - Family Medicine #3, Phoenix, AZ 85013 Phone: 602-406-3153 Fax: 602-406-4122 | |
Dr. Umar Iqbal, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2927 N 7th Ave, Peppertree Building - Window #3, Phoenix, AZ 85013 Phone: 602-406-3153 Fax: 602-406-7176 | |
Jessica Ann Wright, PA-C Family Medicine Medicare: Medicare Enrolled Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-933-1000 | |
Meggan E Bauer, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4250 E Camelback Rd Ste K100, Phoenix, AZ 85018 Phone: 602-224-9218 | |
Dr. James W. Fisher, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12450 N 32nd St Ste 3, Phoenix, AZ 85032 Phone: 602-996-0924 Fax: 602-482-2624 | |
Geoffrey Peter Radoff, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2525 West Greenway, Suite 210, Phoenix, AZ 85023 Phone: 602-993-0200 Fax: 602-993-0207 |